Re-emergence of inflation could be market risk in 2025: Main Street Research's James Demmert

Future Funded
9 followers
1 Video View·Dec 16, 2024
Charlie Bobrinskoy, Ariel Investments vice chairman and James Demmert, Main Street Research vice chairman, joins 'Closing Bell Overtime' to talk the day's market action.
Now let's turn to the broader market action
as we close out the week.
Joining me, Charlie Babrinskoy of Ariel Investments
and James Demert of Main Street Research.
Guys, welcome.
Charlie, S&P 500 value index closed yesterday
with its ninth consecutive daily loss,
longest losing streak on record, I believe.
The index, let's see, equal weight S&P,
up 15% year-to-day versus I think about 27
for things overall.
So it continues to be really rough out there
for value investors.
Why is it gonna get better?
Well, I would say our fund is up 20% this year.
I wouldn't call that really rough.
I would just say not as good
as the large cap growth tech stocks.
So it's been a perfectly good year for value investing,
just not nearly as good as growth investing.
And what we like about this is that we think our names
are reasonably priced here.
A lot of the names that I talk to you about
every time I'm on your show, John,
are trading at 14, 15, 16 times,
not the 27, 28, 29 times in the large cap tech space.
So we think we're getting good returns.
Our customers are happy.
We would not have predicted a 20% return this year,
and we got it.
Reasonable valuations, reasonable growth,
good growth in our companies, not a bad place to be.
Sounds like a tortoise and the hare expectation there.
James, you say to buy any weakness in the market overall,
you predict S&P 61.50 by year end,
but you expect a 10 to 15% correction
at the beginning of 2025,
and that AI stocks and these big stocks
are gonna do worse and then come back.
How do you expect that to work?
Especially, can the market come back
without these big AI names,
big names and AI names coming back too?
Let's see, I'm not hearing James.
Charlie, sorry, let's get your audio fixed.
James, not quite hearing you there.
Charlie, you expect that healthcare and food stocks,
which have responded negatively to the idea of RFK Jr.,
you think they're overdone.
Which ones in particular do you see opportunity in?
Yeah, there are a lot.
I'm glad you called this out.
We think that he has got some ideas
that wouldn't be good for healthcare and food,
but that he's not gonna be as successful
in getting those changes
as the market reaction would have you believe.
So a name like Smucker's,
which has historically been a high teens multiples,
now trading for about 14 times earnings.
That's a very attractive name.
LabCorp is a name that's been,
there's gonna be more testing done going forward,
including on new drug development.
Stock's been hit.
LabCorp trading at a very reasonable valuation.
And then J&J, of course,
one of the best healthcare names.
It's been a great strategy to just buy J&J
and put it away,
is now trading at 14 times forward earnings.
That's a name that's been a premium to the market
for decades and now trading at a discount valuation.
So healthcare and food is a place
that we think has been overly scared
by the prospect of Mr. Kennedy.
Interesting.
James, I believe we got you now.
So you expect a down 10 to 15% in the S&P in Q1,
but we end the year 12 to 15% higher.
How does that work?
Do you expect mega caps
and maybe some of these AI names
to be as strong at the end of the year as at the beginning?
Because if so, they're gonna take quite a round trip.
Yeah, I think it is gonna be a round trip.
It's been very generous for the AI trade
because of the semis,
but we think 2025 is gonna be very different.
Number one, we're gonna have a startling direction,
probably pretty deep for those AI companies
because of their higher valuations.
But we see 2025 as not a Fed-driven market
or all that cash on sidelines,
but the economy and earnings are what drive stocks.
And that'll help Charlie's stocks
because it's gonna broaden.
But we think that that big decline
might be because the Fed is gonna be unable
to lower rates in the first quarter.
That might be startling.
That might have a good sell-off in the tech stocks.
But let's remember one thing.
We're early in the AI transformation.
And as Broadcom suggested and looked at today
with the report, we think there's still lots of legs to AI,
but it's gonna be second-derivative AI companies.
So yes, the NVIDIA's Broadcoms do well in 2025,
but those second-derivative software companies,
telecommunications, catch up.
So what potentially derails your thesis?
If tariffs don't go as you expect,
rates pause for a while?
What really derails us is the pro-growth
deportation of Trump policy igniting inflation again.
The Fed comes back to the table to raise rates.
I think that really calls a very disruptive market,
a very difficult market,
or possibly a U.S. credit downgrade.
Other than that, we think normal correction,
maybe deeper for tech, and people buy that.
If you're not fully invested, you wanna wait for that,
and you wanna buy into that correction in the first quarter.
